Molecular mass of semaglutide and why the figure differs between sources posts 91–111

The bit of molecular mass of semaglutide that nobody enjoys is that the answer changes depending on what you are trying to decide with it. Say what the decision is and the thread will converge.

Coming back to post #90, because the follow-up matters more than the original answer.

Research-use-only semaglutide is not a licensed medicine, is not manufactured to pharmaceutical standards, and is not approved for human use. That is a statement about what it is, not a coded opinion about anything.

This follows post #92 rather than contradicting it.

The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice. Visible particles or frank cloudiness is different and would be reason to contact the supplier.

It is a small point and it changes the answer, which is an awkward combination.

Second-hand on molecular mass of semaglutide, so weight it accordingly — someone whose method I trust told me this and I have not verified it myself.

Approved indications differ by jurisdiction and change. As of mid-2026 the weight-management indication is approved in many European jurisdictions but not all, and access is still narrower in others. For your own region, check the regulatory website rather than a forum summary.

Posting it because the silence on this was starting to look like agreement.

Molecular mass of semaglutide has a well-known answer and a correct answer, and the interesting work is establishing that they are the same. Nobody has done that here yet.

Picking up post #96: that is the part I would want checked first.

Solutions of semaglutide can look faintly opalescent without anything being wrong. Visible particulate, fibres or frank cloudiness are a different observation entirely and are worth raising with the supplier rather than reasoning about.

On post #94 — agreed on the reasoning, with one qualification.

Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the dosing schedule, which admits expectation effects. Weekly versus daily itself is part of the comparison, not a confounding variable to be removed.

Reading it again, the caveat matters more than the finding.

The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent toxicology studies. A signal in rodents does not automatically appear in humans, but it is the reason the compound is contraindicated in people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

I have kept the units in throughout, for the obvious reason.

The 165 to 184 hour half-life range gets quoted as a fixed number. It is a range across a studied population, and individual clearance varies enough that a person's own steady state may be reached earlier or later than the population average implies.

I would put this at better than even and not much better.

Distinguishing three things in the molecular mass of semaglutide discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the recommendation that gets attached to both.

That reframing is the whole thing. The facts I already had.

Semaglutide's structure is a modified backbone with a C18 diacid attached through a spacer. The acylation is the reason for the long half-life and it is also the reason a plain sequence comparison against native GLP-1 is misleading about how the molecule behaves.

On the injection-day question: the labelling for licensed semaglutide allows the day to be changed provided at least two days separate the two injections. That interval is not arbitrary — it is what stops two doses stacking inside one absorption window.

That is my reading. Someone else read the same page differently and was reasonable.